JP2025504017A5 - - Google Patents
Info
- Publication number
- JP2025504017A5 JP2025504017A5 JP2024544889A JP2024544889A JP2025504017A5 JP 2025504017 A5 JP2025504017 A5 JP 2025504017A5 JP 2024544889 A JP2024544889 A JP 2024544889A JP 2024544889 A JP2024544889 A JP 2024544889A JP 2025504017 A5 JP2025504017 A5 JP 2025504017A5
- Authority
- JP
- Japan
- Prior art keywords
- wing segment
- modified oligonucleotide
- compound
- combination according
- linked nucleosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304091P | 2022-01-28 | 2022-01-28 | |
| US63/304,091 | 2022-01-28 | ||
| PCT/IB2023/050687 WO2023144750A1 (en) | 2022-01-28 | 2023-01-26 | Combination therapy for treating hepatitis b virus infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504017A JP2025504017A (ja) | 2025-02-06 |
| JP2025504017A5 true JP2025504017A5 (cg-RX-API-DMAC7.html) | 2026-02-03 |
Family
ID=85172882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544889A Pending JP2025504017A (ja) | 2022-01-28 | 2023-01-26 | Ｂ型肝炎ウイルス感染症を処置するための組合せ療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250092401A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4469161A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025504017A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240144245A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118660704A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023213173B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3243401A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023144750A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202340468A (zh) | 2022-01-10 | 2023-10-16 | 中國大陸商杭州浩博醫藥有限公司 | B型肝炎病毒(hbv)表現之調節 |
| CN118667808B (zh) * | 2023-08-22 | 2025-04-18 | 浙江柏拉阿图医药科技有限公司 | 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61447B1 (sr) | 2011-04-21 | 2021-03-31 | Glaxo Group Ltd | Modulacija ekspresije virusa hepatitisa b (hbv) |
| EP4219767A1 (en) * | 2016-06-17 | 2023-08-02 | F. Hoffmann-La Roche AG | Papd5 and papd7 inhibitors for treating a hepatitis b infection |
| KR20190057277A (ko) * | 2016-06-24 | 2019-05-28 | 에모리 유니버시티 | B형 간염 바이러스 치료용 포스포아미데이트 |
| FI3692040T3 (fi) * | 2017-10-05 | 2023-03-29 | Glaxosmithkline Ip Dev Ltd | Kemiallisia yhdisteitä |
-
2023
- 2023-01-26 US US18/832,756 patent/US20250092401A1/en active Pending
- 2023-01-26 CA CA3243401A patent/CA3243401A1/en active Pending
- 2023-01-26 CN CN202380019294.XA patent/CN118660704A/zh active Pending
- 2023-01-26 WO PCT/IB2023/050687 patent/WO2023144750A1/en not_active Ceased
- 2023-01-26 EP EP23703336.0A patent/EP4469161A1/en active Pending
- 2023-01-26 KR KR1020247028356A patent/KR20240144245A/ko active Pending
- 2023-01-26 AU AU2023213173A patent/AU2023213173B2/en active Active
- 2023-01-26 JP JP2024544889A patent/JP2025504017A/ja active Pending